Real‐world data on safety and efficacy of venetoclax‐based regimens in relapsed/refractory t(11;14) multiple myeloma. (3rd February 2020)

• Record Type: Journal Article
• Authors: Basali, Diana; Chakraborty, Rajshekhar; Rybicki, Lisa; Rosko, Nathaniel; Reed, Janice; Karam, Maryann; Schlueter, Kristen; Dysert, Hayley; Kalaycio, Matt; Valent, Jason
• Is Part Of: British journal of haematology. Volume 189:Number 6(2020)
• Page Start: 1136
• Page End: 1140
• Publication Date: 2020-02-03
• Subjects: venetoclax -- relapsed/refractory multiple myeloma -- amyloidosis -- translocation -- amyloid; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.16454
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic protein BCL‐2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax‐based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non‐haematologic toxicities, most commonly gastrointestinal upset, were observed.